A 54-year-old male patient presented with a 3-day history of fever. Physical examination revealed bilateral edema of lower extremities. Laboratory investigations showed a hemoglobin level of 136 (normal 135-176) g/L, platelet count of 62x10^9^/L (normal 131-362x10^9^/L), lactate dehydrogenase level of 136 (normal 130-240) U/L, alkaline phosphatase level of 428 (normal 100-350) U/L, creatinine level of 0.67 (normal 0.6-1.0) mg/dL, and C-reactive protein level of 22.23 (normal 0-0.30) mg/dL. Serum immunoglobulins were within normal ranges, and monoclonal protein was not detected in serum and urine. Autoimmune workup was negative, and infectious workup was negative, including human herpesvirus-8 (HHV-8) and human immunodeficiency virus. The level of vascular endothelial growth factor (VEGF) was elevated (175, normal \<38.3 pg/mL). Computed tomography demonstrated mild splenomegaly ([Figure 1A](#f1){ref-type="fig"}). Fluorine-18 (18F)-fluorodeoxyglucose positron emission tomography-computed tomography revealed pleural effusion and systemic mild lymphadenopathy with increased 18F-fluorodeoxyglucose uptake ([Figure 1B](#f1){ref-type="fig"}). Three weeks after admission, fever lasted. Blood tests showed anemia (hemoglobin level of 97 g/L), deteriorated thrombocytopenia (platelet count of 28x10^9^/L), and acute kidney injury (creatinine level of 1.57 mg/dL).

A biopsy of the right axillary lymph node revealed atrophic germinal centers with enlarged endothelial cell nuclei, expanded interfollicular zone, endothelial venule proliferation, and a relatively small mature plasma cell number ([Figure 1C](#f1){ref-type="fig"}). Bone marrow biopsy demonstrated hypercellular marrow, megakaryocyte hyperplasia, and mild reticulin fibrosis ([Figure 1D](#f1){ref-type="fig"}). We diagnosed thrombocytopenia, anasarca, fever, reticulin myelofibrosis, and organomegaly (TAFRO) syndrome. The patient was treated with prednisolone (60 mg/day), which was gradually tapered and discontinued after approximately 3 years of treatment. The patient has no recurrence. Written informed consent was obtained from the patient.

The TAFRO syndrome is a newly recognized disease concept ([@ref1]) and is considered to be an uncommon subtype of idiopathic multicentric Castleman disease (iMCD), which is negative for both polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome and HHV-8 ([@ref2]). The pathogenesis of TAFRO syndrome has yet to be fully understood, but it is assumed to be a cytokine storm including VEGF and interleukin-6 ([@ref3]). TAFRO syndrome develops acutely or subacutely and is frequently life threatening, whereas non-TAFRO iMCD usually progresses chronically ([@ref2]).

No optimal treatment has been established, but corticosteroids are the most commonly used first-line therapy. Other choices are immunosuppressants, immunomodulators, and cytotoxic chemotherapy. Because late relapses are not infrequent, long-term follow-up is warranted for patients with TAFRO syndrome.
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![**A-D.** (A) Computed tomography showing a slightly enlarged spleen. (B) Fluorine-18 (18F)-fluorodeoxyglucose positron emission tomography-computed tomography showing pleural fluid and small lymphadenopathy with augmented 18F-fluorodeoxyglucose uptake. (C) Biopsy of the right axillary lymph node showing atrophic germinal centers with enlarged endothelial cell nuclei, expanded interfollicular zone, dense endothelial venule proliferation, and a few mature plasma cells (hematoxylin and eosin stain, original magnification x10). (D) Bone marrow biopsy showing hypercellular marrow and megakaryocytic hyperplasia along with reticulin fibrosis (silver stain, original magnification x20).](BMJ-37-293-g1){#f1}
